These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6817016)

  • 1. Amidolytic end-point methods for factor VIIIC inhibitors.
    Mackie IJ; Seghatchian MJ
    Med Lab Sci; 1982 Oct; 39(4):345-50. PubMed ID: 6817016
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acquired hemophilia A due to factor VIIIC inhibitor: detection of circulating immune complexes containing factor VIIIC but not factor VIIIR].
    Pfyffer M; Kistler HJ; von Felten A
    Schweiz Med Wochenschr; 1983 Oct; 113(40):1456-9. PubMed ID: 6417777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants.
    de Maistre E; Wahl D; Perret-Guillaume C; Regnault V; Clarac S; Briquel ME; Andre E; Lecompte T
    Thromb Haemost; 1998 Jan; 79(1):237-8. PubMed ID: 9459356
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of phospholipid on factor VIII inactivation.
    Barrowcliffe TW; Kemball-Cook G; Gray E
    Prog Clin Biol Res; 1984; 150():251-63. PubMed ID: 6431431
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor VIIIc inhibitors: an automated assay.
    Luddington R; Jennings I
    Med Lab Sci; 1992 Jun; 49(2):135-7. PubMed ID: 1487978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The analysis of factor VIII.
    Giddings JC
    Med Lab Sci; 1982 Oct; 39(4):339-43. PubMed ID: 6817015
    [No Abstract]   [Full Text] [Related]  

  • 7. A rebuttal: Issues with the assay of factor VIII activity in plasma and factor VII concentrates.
    Rosén S
    Thromb Haemost; 2001 Oct; 86(4):1132-3. PubMed ID: 11686346
    [No Abstract]   [Full Text] [Related]  

  • 8. [Determination of clotting factor VIII activity in mammals using the one-stage clotting and the chromogenic methods].
    Lutze G; Lutze G; Kutschmann K; Schröpel M
    Berl Munch Tierarztl Wochenschr; 2002; 115(7-8):297-302. PubMed ID: 12174728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis.
    Devreese K; Wijns W; Combes I; Van kerckhoven S; Hoylaerts MF
    Thromb Haemost; 2007 Sep; 98(3):600-13. PubMed ID: 17849049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three methods for measuring factor VIII levels in plasma.
    Chandler WL; Ferrell C; Lee J; Tun T; Kha H
    Am J Clin Pathol; 2003 Jul; 120(1):34-9. PubMed ID: 12866370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
    Barrowcliffe TW; Raut S; Sands D; Hubbard AR
    Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancies in measured factor VIII activity in patients treated with factor VIII concentrate of human or porcine origin.
    Teitel JM; Lau HK; Garvey MB
    Thromb Haemost; 2002 Jul; 88(1):159-60. PubMed ID: 12152659
    [No Abstract]   [Full Text] [Related]  

  • 13. Monocyte procoagulant activity: development of a microtitre plate chromogenic assay.
    Baker P; Joshi M; Luddington R
    Br J Biomed Sci; 1994 Dec; 51(4):328-31. PubMed ID: 7756938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of factor VIII versus nonspecific inhibitors.
    Goldsmith JC
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):3-6. PubMed ID: 8480195
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma exchange in non-haemophiliac patients with inhibitors to factor VIIIC.
    Erskine JG; Burnett AK; Walker ID; Davidson JF
    Br Med J (Clin Res Ed); 1981 Sep; 283(6294):760. PubMed ID: 6791738
    [No Abstract]   [Full Text] [Related]  

  • 16. [Blood clotting diagnosis with chromogenic substrates].
    Róka L; Rasche H
    Internist (Berl); 1980 Apr; 21(4):189-94. PubMed ID: 6998907
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blood coagulation monitoring in oral anticoagulant therapy using chromogenic substances].
    Pindur G; Seifried E; Joos A; Rasche H
    Med Lab (Stuttg); 1981; 34(3):88-91. PubMed ID: 7231353
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of a simple chromogenic factor VIII assay for clinical use.
    Wagenvoord RJ; Hendrix HH; Hemker HC
    Haemostasis; 1989; 19(4):196-204. PubMed ID: 2509307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogenic assays for equine coagulation factors VII, VIII:C, IX, and X, and C1-esterase inhibitor.
    Topper MJ; Prasse KW
    Am J Vet Res; 1998 May; 59(5):538-41. PubMed ID: 9582952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.